February 23, 2012 9:01 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Genzyme, a Sanofi company (NYSE: SNY), announced today theEuropean Medicines Agency (EMA) has accepted the filing of the marketingauthorization application (MAA) for once-daily oral teriflunomide for thetreatment of relapsing forms of multiple sclerosis (MS). Acceptance of the MAAstarts the EMA's review process.“The filing represents another important milestone for teriflunomide andbrings us one step closer to offering a new treatment option to patients withrelapsing MS,” said Bill Sibold, Senior Vice President, Head of MultipleSclerosis, Genzyme. “As an oral therapy with a promising clinical profile,teriflunomide is extremely well positioned to provide an alternativetherapeutic option to patients who are currently taking injectable therapies.Those injectable therapies make up approximately 80 percent of the MS markettoday.”
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.